A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Study Purpose

The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics [PK]) in pediatric participants with moderately to severely active UC.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 2 Years - 17 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Medically stable on the basis of physical examination, medical history, and vital signs, performed at screening.
Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and acknowledged by the investigator.
  • - Must have had UC diagnosed prior to screening.
  • - Have moderately to severely active UC, defined as a baseline Mayo score of 6 through 12, inclusive, with a screening Mayo endoscopy subscore greater than or equal to (>=) 2 as determined by a central review of the video of the endoscopy.
  • - A participant who has had extensive colitis for >= 8 years, or disease limited to the left side of the colon for >= 10 years, must: a) have had a full colonoscopy to assess for the presence of dysplasia within 1 year before the first administration of study intervention or b) have a full colonoscopy with surveillance for dysplasia as the baseline endoscopy during the screening period.
Results from these surveillance biopsies must be negative for dysplasia (low-grade, high-grade, or indeterminant) prior to the first administration of study intervention.
  • - Females of childbearing potential must have a negative highly sensitive urine pregnancy test at screening and at Week I-0 prior to study intervention administration.

Exclusion Criteria:

  • - Have UC limited to the rectum only or to less than (<) 20 centimeter (cm) of the colon.
  • - Presence or history of colonic or small bowel obstruction within 6 months prior to screening, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy) - Have a history of latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis, or have had a nontuberculous mycobacterial infection prior to screening.
  • - Presence or history of any malignancy including presence or history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (example, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic areas) and monoclonal gammopathy of undetermined significance, or clinically significant hepatomegaly or splenomegaly.
- Has known allergies, hypersensitivity, or intolerance to ustekinumab or its excipients

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04630028
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Janssen Research & Development, LLC
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Janssen Research & Development, LLC Clinical Trial
Principal Investigator Affiliation Janssen Research & Development, LLC
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Belgium, Germany, Hungary, Japan, Poland, Russian Federation, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Colitis, Ulcerative
Arms & Interventions

Arms

Experimental: Induction Period (I): Ustekinumab

All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).

Experimental: Maintenance (M) Period: Ustekinumab once every 8 Week (q8w)

Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.

Experimental: Maintenance (M) Period: Ustekinumab once every 12 Week (q12w)

Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.

Interventions

Drug: - Ustekinumab Dose Based on BSA and Body Weight

As per BSA and body weight Ustekinumab will be administered SC and IV.

Drug: - Matching Placebo

Placebo will be administered subcutaneously.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Nemours DuPont Hospital for Children, Wilmington, Delaware

Status

Recruiting

Address

Nemours DuPont Hospital for Children

Wilmington, Delaware, 19803

Atlanta, Georgia

Status

Recruiting

Address

Children's Center for Digestive Health Care

Atlanta, Georgia, 30342

Mayo Clinic, Rochester, Minnesota

Status

Recruiting

Address

Mayo Clinic

Rochester, Minnesota, 55905

Morristown Memorial Hospital, Morristown, New Jersey

Status

Recruiting

Address

Morristown Memorial Hospital

Morristown, New Jersey, 07962

Levine Children's at Atrium Health, Charlotte, North Carolina

Status

Recruiting

Address

Levine Children's at Atrium Health

Charlotte, North Carolina, 28207

Cleveland, Ohio

Status

Recruiting

Address

University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106

Penn State Hershey Children's Hospital, Hershey, Pennsylvania

Status

Recruiting

Address

Penn State Hershey Children's Hospital

Hershey, Pennsylvania, 17033

Cook Childrens Medical Center, Fort Worth, Texas

Status

Recruiting

Address

Cook Childrens Medical Center

Fort Worth, Texas, 76104

Pediatric Specialists Of Virginia, Fairfax, Virginia

Status

Recruiting

Address

Pediatric Specialists Of Virginia

Fairfax, Virginia, 22031

International Sites

Brussel, Belgium

Status

Recruiting

Address

Universitair Kinderziekenhuis Koningin Fabiola

Brussel, , 1020

Cliniques Universitaires Saint-Luc, Brussel, Belgium

Status

Recruiting

Address

Cliniques Universitaires Saint-Luc

Brussel, , 1200

UZ Gent, Gent, Belgium

Status

Recruiting

Address

UZ Gent

Gent, , 9000

UZ Brussel, Jette, Belgium

Status

Recruiting

Address

UZ Brussel

Jette, , 1090

UZ Leuven, Leuven, Belgium

Status

Recruiting

Address

UZ Leuven

Leuven, , 3000

Universitätsklinikum Aachen, Aachen, Germany

Status

Recruiting

Address

Universitätsklinikum Aachen

Aachen, , 52074

Berlin, Germany

Status

Recruiting

Address

Charite-Universitätsmedizin Berlin - Berlin

Berlin, , 13353

Universitatsklinikum Essen, Essen, Germany

Status

Recruiting

Address

Universitatsklinikum Essen

Essen, , 45147

Medizinische Hochschule Hannover, Hannover, Germany

Status

Completed

Address

Medizinische Hochschule Hannover

Hannover, , 30625

Dr. von Haunersches Kinderspital, Munich, Germany

Status

Recruiting

Address

Dr. von Haunersches Kinderspital

Munich, , 80337

KUNO Klinik St. Hedwig, Regensburg, Germany

Status

Recruiting

Address

KUNO Klinik St. Hedwig

Regensburg, , 93049

Universitätsklinikum Ulm, Ulm, Germany

Status

Completed

Address

Universitätsklinikum Ulm

Ulm, , 89075

Semmelweis Egyetem, Budapest, Hungary

Status

Recruiting

Address

Semmelweis Egyetem

Budapest, , 1083

Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary

Status

Recruiting

Address

Debreceni Egyetem Klinikai Kozpont

Debrecen, , 4032

Miskolc, Hungary

Status

Recruiting

Address

Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz

Miskolc, , 3526

Nyiregyhaza, Hungary

Status

Recruiting

Address

Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz

Nyiregyhaza, , 4400

Szeged, Hungary

Status

Recruiting

Address

Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum

Szeged, , 6720

Juntendo University Hospital, Bunkyo-Ku, Japan

Status

Recruiting

Address

Juntendo University Hospital

Bunkyo-Ku, , 113-8431

Gunma University Hospital, Gunma, Japan

Status

Recruiting

Address

Gunma University Hospital

Gunma, , 371-0034

Kindai University Nara Hospital, Ikoma, Japan

Status

Recruiting

Address

Kindai University Nara Hospital

Ikoma, , 630-0293

Kurume University Hospital, Kurume, Japan

Status

Recruiting

Address

Kurume University Hospital

Kurume, , 830-0011

Saitama Children's Medical Center, Saitama-shi, Japan

Status

Recruiting

Address

Saitama Children's Medical Center

Saitama-shi, , 330-8777

Miyagi Children's Hospital, Sendai, Japan

Status

Recruiting

Address

Miyagi Children's Hospital

Sendai, , 989-3126

Setagaya-ku, Japan

Status

Recruiting

Address

National Center for Child Health and Development

Setagaya-ku, , 157-8535

Jichi Medical University Hospital, Shimotsuke, Japan

Status

Recruiting

Address

Jichi Medical University Hospital

Shimotsuke, , 329-0498

Mie University Hospital, Tsu, Japan

Status

Recruiting

Address

Mie University Hospital

Tsu, , 514-8507

Szpital im. M. Kopernika, Gdansk, Poland

Status

Completed

Address

Szpital im. M. Kopernika

Gdansk, , 80-803

Krakow, Poland

Status

Recruiting

Address

Uniwersytecki Szpital Dzieciecy w Krakowie

Krakow, , 30-663

Korczowski Bartosz, Gabinet Lekarski, Rzeszow, Poland

Status

Recruiting

Address

Korczowski Bartosz, Gabinet Lekarski

Rzeszow, , 35-302

GASTROMED Sp. z o.o., Torun, Poland

Status

Recruiting

Address

GASTROMED Sp. z o.o.

Torun, , 87-100

WIP Warsaw IBD Point Profesor Kierkus, Warszawa, Poland

Status

Recruiting

Address

WIP Warsaw IBD Point Profesor Kierkus

Warszawa, , 00-728

Warszawa, Poland

Status

Recruiting

Address

Instytut Pomnik - Centrum Zdrowia Dziecka

Warszawa, , 04-730

Kazan State Medical University, Kazan, Russian Federation

Status

Completed

Address

Kazan State Medical University

Kazan, , 420138

Moscow, Russian Federation

Status

Completed

Address

Russian National Research Medical University named after N.I.Pirogov

Moscow, , 119571

Moscow, Russian Federation

Status

Completed

Address

FSBI 'Scientific Centre of Children Health' of the Russian Academy of Medical Sciences

Moscow, , 119991

Nizhny Novgorod, Russian Federation

Status

Completed

Address

Privolzhsky Research Medical University of Ministry of Health of Russian Federation

Nizhny Novgorod, , 603950

Saratov State Medical University, Saratov, Russian Federation

Status

Completed

Address

Saratov State Medical University

Saratov, , 410054

Yaroslavl, Russian Federation

Status

Completed

Address

Yaroslavl Regional Children's Clinical Hospital

Yaroslavl, , 150032

Birmingham Children's Hospital, Birmingham, United Kingdom

Status

Recruiting

Address

Birmingham Children's Hospital

Birmingham, , B4 6NH

Cambridge, United Kingdom

Status

Recruiting

Address

Cambridge University Hospitals NHS Foundation Trust

Cambridge, , CB2 0QQ

Royal London Hospital, London, United Kingdom

Status

Recruiting

Address

Royal London Hospital

London, , E1 2AT